Geode Capital Management LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 35.9% during the first quarter, Holdings Channel reports. The fund owned 359,640 shares of the biotechnology company’s stock after buying an additional 95,084 shares during the period. Geode Capital Management LLC’s holdings in Heron Therapeutics were worth $5,394,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in HRTX. Highbridge Capital Management LLC boosted its stake in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock worth $206,000 after buying an additional 252 shares during the last quarter. Legal & General Group Plc boosted its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 69,352 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 1,897 shares during the last quarter. Teachers Advisors LLC boosted its stake in Heron Therapeutics by 3.4% in the fourth quarter. Teachers Advisors LLC now owns 57,858 shares of the biotechnology company’s stock worth $758,000 after buying an additional 1,924 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock worth $330,000 after buying an additional 2,233 shares during the last quarter.

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) traded up 2.56% during trading on Friday, hitting $16.00. The stock had a trading volume of 773,366 shares. Heron Therapeutics, Inc. has a 52 week low of $12.21 and a 52 week high of $22.01. The company’s 50 day moving average price is $15.38 and its 200 day moving average price is $14.57.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. Analysts anticipate that Heron Therapeutics, Inc. will post ($3.74) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Heron Therapeutics, Inc. (HRTX) Position Raised by Geode Capital Management LLC” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://theolympiareport.com/2017/08/12/heron-therapeutics-inc-hrtx-position-raised-by-geode-capital-management-llc.html.

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $31.00 price objective (up from $30.00) on shares of Heron Therapeutics in a research report on Thursday, May 11th. ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Cowen and Company reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Friday, May 26th. Aegis reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $26.00 target price on shares of Heron Therapeutics in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.00.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.